文献速递临床试验与 GCP

磷酸川芎嗪治疗肺动脉高压的疗效与安全性:随机对照研究方案

Efficacy and safety of tetramethylpyrazine phosphate on pulmonary hypertension: study protocol for a randomized controlled study.
PubMed 文献 · Trials · 2019-12-16

本研究为随机单盲临床试验,计划招募120例稳定期1型或4型肺动脉高压患者,按对照:治疗=1:2随机分组,两组均接受常规治疗,治疗组加用口服磷酸川芎嗪100 mg每日三次共16周,评估其疗效与安全性,目前为研究方案阶段。

要点

  • 磷酸川芎嗪在肺动脉高压中的疗效尚不明确,本研究旨在评估其治疗作用与安全性。
  • 纳入标准包括静息海平面平均肺动脉压>20 mmHg且肺毛细血管楔压<15 mmHg的稳定期1型或4型患者。
  • 治疗组口服磷酸川芎嗪100 mg每日三次,共16周,随访4、8、12、16周记录症状与依从性。

核心结论

  • 本研究旨在确定磷酸川芎嗪对肺动脉高压患者的疗效与安全性,目前仅为研究方案,尚无结果结论。

研究设计与样本

  • 随机、单盲临床试验,设磷酸川芎嗪治疗组与对照组,计划招募120例肺动脉高压患者。
  • 按对照:治疗=1:2比例随机分组,两组均接受常规治疗,治疗组加用口服磷酸川芎嗪100 mg每日三次共16周。
  • 随访时间点为第4、8、12、16周,记录症状与患者依从性。

关键数值与推荐

  • 纳入标准:静息海平面平均肺动脉压>20 mmHg且肺毛细血管楔压<15 mmHg。
  • 纳入标准:稳定期1型或4型肺动脉高压,年龄15-70岁。
  • 纳入标准:6分钟步行距离100-450米,WHO肺动脉高压功能分级II、III或IV级。
  • 干预:治疗组口服磷酸川芎嗪100 mg,每日三次,持续16周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tetramethylpyrazine (TMP), an active ingredient in the traditional Chinese herbal medicine Rhizoma Chuanxiong, has been used clinically for the prevention and treatment of cardiovascular disease. The benefits of TMP are largely attributed to its anti-oxidative and vasodilative properties. However, the efficacy of TMP in the treatment of pulmonary hypertension (PH) is unknown. We hypothesized that TMP may have a therapeutic effect in patients with PH. METHODS/DESIGN: A randomized, single-blinded, clinical study with a TMP treatment group and a control group will be conducted to evaluate the efficacy and safety of TMP intervention in patients with PH. The recruitment target is 120 subjects meeting the following criteria: (i) at rest and at sea level, mean pulmonary artery pressure above 20 mmHg and pulmonary capillary wedge pressure below 15 mmHg; (ii) type 1 or 4 PH in the stable phase; (iii) age 15-70 years; (iv) 6-min walk distance between 100 and 450 m; (v) World Health Organization (WHO) functional classification of pulmonary hypertension of II, III, or IV. Subjects will be assigned randomly into two groups at a ratio of 1:2 (control:TMP). Both groups will receive routine treatment, and the treatment group will also receive oral TMP (100 mg) three times a day for 16 weeks. All patients will be followed up for 4, 8, 12, and 16 weeks; symptoms and patient compliance will be recorded. DISCUSSION: We aimed to determine the efficacy and safety of TMP for the treatment of PH. TRIAL REGISTRATION: Chinese Clinical Trial Register, ChiCTR1800018664. Registered on 2 October 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Chen Y, He W, Ouyang H, et al. Efficacy and safety of tetramethylpyrazine phosphate on pulmonary hypertension: study protocol for a randomized controlled study. Trials. 2019. PMID: 31842950. doi:10.1186/s13063-019-3770-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。